Cancer
WF2304/A172401: Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics
Description
This prospective cohort study will examine the association between cannabis and cannabinoid use and cancer-related symptoms for a period of one year in adults with newly diagnosed breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer (NSCLC) who are planning or recently started to receive one or more systemic cancer directed therapies with chemotherapy and/or immune check point inhibitors (ICIs) targeting PD-1, PD-L1 or CTLA-4. In a subsample of non-small cell lung cancer patients, this study also examines potential drug interactions and impacts of cannabis and cannabinoid use on inflammatory and immune response.
Inclusion Notes
For a full description of this trial, please go to the listing on www.clinicaltrials.gov
For Medical Personnel
Inclusion Criteria
- Adults aged 18 years or older with one of the following newly diagnosed cancers: breast cancer, colorectal cancer, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer.
- Planned treatment with systemic chemotherapy (single or multi-agent, includes targeted therapy) and/or immune checkpoint inhibitor therapy (targeting PD-1, PD-L1 or CTLA-4). If unable to engage participant before treatment starts, enrollment is allowed up to the start of Cycle 2 treatment.
- Participants must be able to comprehend English or Spanish (for survey completion).
- Participant must have a working email address and be willing to complete surveys online. This can be completed at home, in the clinic or other location.
- Completion of the confidential Self-reported Screening Survey and receipt of a screening result - eligible for enrollment.
Start Date
Tuesday, April 29, 2025
Principal / Contact Name
Mohmad A. Bulbul, MD